Literature DB >> 7985383

Comparative pharmacokinetics of fenbendazole in buffalo and cattle.

M R Knox1, P M Kennedy, D R Hennessy, J W Steel, L F Le Jambre.   

Abstract

Swamp buffalo (Bubalus bubalis) and Droughtmaster cattle (Bos indicus x B. taurus), fitted with gastrointestinal cannulae, were dosed intraruminally with fenbendazole at 7.5 mg/kg liveweight, together with a chromium oxide capsule and a pulse dose of NaCoEDTA, to estimate the flow dynamics of the digesta in the rumen and duodenum. The concentrations of fenbendazole (FBZ) metabolites were measured in plasma and duodenal fluid collected over 120 h. In plasma, significantly lower peak concentrations and earlier disappearance of FBZ and its sulphoxide (OFZ) metabolite were observed in buffalo, which considerably reduced systemic availability in comparison with cattle. The availability of OFZ in the duodenal fluid of buffalo was significantly lower, whereas FBZ disposition was similar to that in cattle. The turnover rate of fluid in the rumen was higher in buffalo than in cattle, while the flow parameters for other digesta were similar in the two species. It is concluded that the decreased absorption of drug in buffalo was attributable to the shorter residence time of the dose in the rumen, and probably in the entire gastrointestinal tract. This may reduce the efficacy of treatment and indicate the need for higher dose rates for benzimidazole anthelmintics in buffalo than in cattle.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7985383     DOI: 10.1007/BF01839270

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN: 0165-7380            Impact factor:   2.459


  15 in total

1.  Triclabendazole in the treatment of Fasciola gigantica infection in swamp buffalo (Bubalus bubalis).

Authors:  S E Estuningsih; P Stevenson; M R Knox
Journal:  Aust Vet J       Date:  1990-06       Impact factor: 1.281

2.  Pharmacokinetics and dosage regimen of cephalexin in buffalo calves (Bubalus bubalis) following single intravenous and intramuscular administration.

Authors:  S K Garg; R K Chaudhary; A K Srivastava; B D Garg
Journal:  Vet Res Commun       Date:  1990       Impact factor: 2.459

3.  Effects of diet on plasma concentrations of oral anthelmintics for cattle and sheep.

Authors:  S M Taylor; T R Mallon; W J Blanchflower; D G Kennedy; W P Green
Journal:  Vet Rec       Date:  1992-03-28       Impact factor: 2.695

4.  Toxocara vitulorum: treatment based on the duration of the infectivity of buffalo cows (Bubalus bubalis) for their calves.

Authors:  J A Roberts
Journal:  J Vet Pharmacol Ther       Date:  1989-03       Impact factor: 1.786

5.  The oxidative metabolism of fenbendazole: a comparative study.

Authors:  C R Short; W Flory; L C Hsieh; S A Barker
Journal:  J Vet Pharmacol Ther       Date:  1988-03       Impact factor: 1.786

6.  Disposition of fenbendazole in cattle.

Authors:  C R Short; S A Barker; L C Hsieh; S P Ou; T McDowell; L E Davis; C A Neff-Davis; G Koritz; R F Bevill; I J Munsiff
Journal:  Am J Vet Res       Date:  1987-06       Impact factor: 1.156

7.  Disposition of fenbendazole in the goat.

Authors:  C R Short; S A Barker; L C Hsieh; S P Ou; L E Davis; G Koritz; C A Neff-Davis; R F Bevill; I J Munsiff; G C Sharma
Journal:  Am J Vet Res       Date:  1987-05       Impact factor: 1.156

8.  Pharmacokinetics of fenbendazole in sheep.

Authors:  S E Marriner; J A Bogan
Journal:  Am J Vet Res       Date:  1981-07       Impact factor: 1.156

9.  Potentiation of the anthelmintic activity of oxfendazole by parbendazole.

Authors:  D R Hennessy; E Lacey; R K Prichard; J W Steel
Journal:  J Vet Pharmacol Ther       Date:  1985-09       Impact factor: 1.786

10.  Metabolite concentrations in plasma following treatment of cattle with five anthelmintics.

Authors:  R K Prichard; D R Hennessy; J W Steel; E Lacey
Journal:  Res Vet Sci       Date:  1985-09       Impact factor: 2.534

View more
  1 in total

1.  Effects of diet and species on the pharmacokinetics of fenbendazole in cattle.

Authors:  M R Knox; J W Steel
Journal:  Vet Res Commun       Date:  1997-01       Impact factor: 2.459

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.